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ASSOCIATION BETWEEN CIGARETTE SMOKING AND OVARIAN RESERVE 
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Cigarette smoking in women has been associated with adverse reproductive 
outcomes such as reduced ovarian reserve, poorer in vitro fertilization (IVF) outcomes 
and increased adverse pregnancy outcomes. This study examined the association of 
smoking with ovarian reserve in a cross-sectional study of women seeking fertility 
treatment, and potential effect modification by race and NAT2 acetylator phenotype. 
Data from 265 women from the Louisville Tobacco Smoke, Genetic 
Susceptibility, and Infertility (LOUSSI) Study were analyzed.  A total of 265 women 
were recruited through a single infertility clinic between September 2016 and June 2018. 
Information on current smoking status was assessed using a structured questionnaire and 
confirmed by cotinine assay. Single nucleotide polymorphisms in NAT2 were genotyped 
to determine acetylator status and serum anti-Müllerian hormone (AMH) level was used 
to assess ovarian reserve. The association of smoking with ovarian reserve was assessed 
using linear and logistic regression models with adjustment for potential confounders.
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Effect modification by race and NAT2 phenotype were assessed by including interaction 
terms in the regression models. 
Overall, smoking was not significantly associated with ovarian reserve. Results 
suggest that heavy smoking and higher pack-years of exposure may decrease ovarian 
reserve. Although most associations were not statistically significant, the effect of 
smoking on ovarian reserve was more pronounced among non-Hispanic Black women 
and slow NAT2 acetylators. These results are based on a small clinical population and 
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Infertility and impaired fecundity among women of reproductive age remain an 
important public health issue. It is estimated that 10.9% of women between the ages of 
15-44 have impaired fecundity [1]. Among married women 15-44 years of age, 6.0% are 
infertile and non-Hispanic black women are more likely to be infertile than non-Hispanic 
white (NHW) women [1]. Among women aged 15-44, 12% had ever used infertility 
services with use highest among older women, NHW women and women with higher 
educational levels and income [1, 2].  The median per-person costs of infertility treatment 
ranged from $1,182 for medications only, to $24,373 and $38,015 for in-vitro fertilization 
(IVF) and IVF with donor egg groups, respectively. Eighty- five percent of IVF costs are 
paid out of pocket [3, 4]. In addition to the financial burden, the diagnosis and treatment 
of infertility is associated with psychological and emotional consequences such as 
anxiety and depression [5, 6].  
Causes of infertility include ovulatory disorders, tubal damage, uterine or 
peritoneal problems and male factors, and in 15% to 30% of cases, etiology is unknown 
[7, 8]. Ovulatory dysfunction or ovarian failure accounts for 20% of cases of infertility 
[8]. Diminished ovarian reserve (DOR) defined as a condition where the response to 




is present in about 27.5% of women undergoing IVF [9]. Markers of ovarian reserve 
include anti-Müllerian hormone (AMH) serum levels and antral follicle count (AFC) as 
assessed by transvaginal ultrasound [10, 11]. AMH levels and AFC are important 
predictors of IVF success with lower levels reflecting smaller follicular pool and ovarian 
reserve [10-15]. Major predictors of ovarian reserve include age, age at menarche, parity, 
obesity and race/ethnicity [16]. 
Cigarette smoking in women has been associated with adverse reproductive 
outcomes such as reduced ovarian reserve, poorer IVF outcome and increased adverse 
pregnancy outcomes [17-22]. Studies of the association of active smoking with ovarian 
reserve have been inconsistent. No epidemiological studies have been conducted to 
explore potential gene-environment interaction as a possible cause of inconsistency in 
results [23, 24]. 
N-acetyltransferase2 (NAT2) is an important enzyme in the conjugation of certain 
drugs and other xenobiotics such as tobacco smoke, caffeine and pesticides [25, 26]. The 
effects of NAT2 polymorphisms and their interaction with smoking on different cancer 
risks have been established [27-29]. However, only one epidemiological study has been 
conducted on the effects of NAT2 polymorphisms and possible interaction with smoking 
on fertility and related outcomes among women [24]. No studies have explored the 




B. OBJECTIVE AND SPECIFIC AIMS 
The primary objective of the study is to examine the relationship between active 
cigarette smoking and ovarian reserve as measured by AMH levels in females seeking 
fertility treatment. Racial disparity by ethnicity (African-American, NHW) will be 
explored by comparing the association in African-American (AA) with NHW women. In 
addition, potential effect modification by NAT2 acetylator status on ovarian reserve will 
be evaluated. 
The specific aims of the study are as follows; 
1(a). To determine if current active smoking, as measured by urinary cotinine 
levels and questionnaire, is associated with ovarian reserve (as measured by AMH) 
among women seeking fertility treatment after controlling for potential confounders such 
as age, body mass index (BMI), age at menarche, parity and PCOS status. 
Hypothesis: Smoking is associated with ovarian reserve with smokers having decreased 
ovarian reserve compared to nonsmokers. 
1(b). To determine if a dose-response relationship exists between current active 
smoking (as measured by number of cigarettes smoked per day) and ovarian reserve. The 
dose of exposure will be assessed based on response to the smoking questionnaire. 
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Hypothesis: A dose-response relationship exists between active smoking and ovarian 
reserve with a higher level of exposure being associated with decreased ovarian reserve. 
1(c). To determine if a dose-response relationship exists between cumulative 
lifetime smoking (as measured by pack-years reported on the questionnaire) and ovarian 
reserve.  
Hypothesis: A dose-response relationship exists between cumulative lifetime exposure to 
smoking and ovarian reserve with longer pack-years of exposure being associated with 
decreased ovarian reserve. 
2. To determine if the association of current active smoking with ovarian reserve 
differ by race, comparing African-American with Caucasians (NHW) women. 
Hypothesis: The associations between active smoking and ovarian reserve will be 
different when comparing AA to NHW women (i.e. there is a significant interaction 
between smoking and race when examining their joint effects on ovarian reserve). 
3. To determine if there is an interaction between current active smoking and 
NAT2 acetylator status on ovarian reserve.  
Hypothesis: There is a significant interaction between smoking and NAT2 acetylator 
status when examining their joint effects on ovarian reserve, with slow acetylators having 




C. BACKGROUND AND SIGNIFICANCE 
Infertility is defined as failure to achieve clinical pregnancy after 12 months or 
more of regular unprotected sexual intercourse [30].  A diagnosis of infertility is made 
based on detailed medical history and physical examination followed by diagnostic 
evaluations to identify the underlying etiology [11]. Diagnostic evaluation for infertility 
includes tests for ovarian function, uterine abnormalities, cervical factors, tubal patency, 
peritoneal factors and semen analysis [11, 31, 32]. 
Infertility is divided into two major subtypes of primary and secondary infertility 
[30]. Secondary infertility refers to the inability of a woman to get pregnant or carry a 
pregnancy to live birth following a previous pregnancy or live birth. Diagnosis of primary 
infertility is made in women with no prior history of conception or live birth [30]. 
Epidemiology 
Globally, infertility affects 48.5 million couples. Of these, 19.2 million have 
primary infertility and 29.3 million have secondary infertility [33]. The prevalence of 
infertility has increased globally [33]. In 2010, the prevalence of secondary infertility 
increased with age, from 2.6% in women aged 20–24 to 27.1% in women aged 40–44 
years [33]. The trends were reversed for primary infertility with prevalence higher among 
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women aged 20-24 (2.7%) compared to women aged 25–29 (2.0%) and women aged 30–
44 (1.6%) [33]. 
In the United States, the percentage of all married women 15-44 years of age who 
are infertile was 6.0% between 2006 to 2010 and increased to 6.7% in 2015 [1, 34]. The 
prevalence of infertility increased with age. Among currently married women 15-44 years 
with no prior live birth, the prevalence was 8.7% among women aged 15-29,11.0% in 
women 30-34, 23.0% in women 35-39 and 26.2% in women 40-44 years [34].  
An estimated 7.3 million women 15-44 years have ever received any infertility 
services between 2011 to 2015 [2, 34]. The use of infertility services varied by 
socioeconomic status and race/ethnicity. Among women 25-44 years of age, ever use of 
fertility services ranged from 9.5% in women with no high school diploma to 22.6 % in 
women with a master’s degree or higher [2]. Use of fertility service was higher among 
women 300-399 % the above poverty level (21.2%) compared to women less than 100% 
below poverty level (12.9%) [2]. Among the racial/ethnic groups, Non-Hispanic black 
(African-Americans) had lower ever use of fertility services (11.0%) than non-Hispanic 
white (19.1%), or Hispanic (13.2%) women [2]. 
Some of the disparities in use of infertility services have been linked to the 
significant costs of medical services and the lack of adequate health insurance to cover 
necessary diagnostic tests or treatments [2, 35, 36]. The estimated median cost per IVF 
cycle rose from $9226 in 2001 to about $12,513 in 2006 [37, 38]. The median per-person 
cost of infertility treatment ranged from $1,182 for medications only, to $24,373 and 
$38,015 for invitro fertilization (IVF) and IVF with donor egg groups, respectively [3]. In 
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the United States, only 25% of health care plans cover infertility treatment with 85% of 
IVF costs being paid out of pocket [4, 36]. 
Aside from the financial burden associated with infertility, the condition is 
associated with psychological and emotional consequences such as anxiety and 
depression [5, 6]. In a cross-sectional survey of infertile women referred for infertility 
treatment, 40.8% had depression and 86.8% had anxiety [5]. The duration of infertility 
predicted 18% of anxiety and 25% of depression among infertile women [6]. 
Causes of infertility 
Conception requires the timely release of a matured oocyte; adequate number of 
progressively motile and normal spermatozoa capable of reaching and fertilizing the 
oocyte; patent fallopian tubes for free passage of the sperm to reach the oocyte for 
fertilization and migration of zygote/embryo to the uterus; and a well primed 
endometrium that allows for implantation [11, 31, 32]. Biological, anatomical or 
functional defects at any of these stages may lead to infertility. The probable causes of 
infertility are classified into tubal factor, uterine or peritoneal problems, male factor and 
ovulatory dysfunction [7, 8]. An estimated 40% of couples with infertility have a 
combination of factors while 15% may not display any objective alterations in fertility 
function [8].  
Tubal factors account for 14% of cases of infertility and include conditions that 
causes tubal obstruction and /or peritoneal adhesions [7]. Conditions that affect the 
integrity of the uterine cavity and peritoneum such as endometriosis, uterine fibroids, 
uterine synechiae may impact fertility [7, 8, 11, 32]. The male factors include conditions 
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that affects the concentration, motility, vitality and morphology of sperm cells [7, 8, 31, 
32].  
Ovulatory Dysfunction. Ovulation normally occurs when an ovary releases a 
single mature oocyte every month and women who ovulate typically have regular and 
consistent menstrual duration and flow [7]. Ovulatory dysfunction commonly results in 
menstrual disturbances and account for 40% of infertility in women [11, 39]. Causes of 
ovulatory dysfunction include polycystic ovary syndrome (PCOS), obesity, weight gain 
or loss, strenuous exercise, thyroid dysfunction, and hyperprolactinemia [7, 8, 11]. 
Methods of assessing ovulatory dysfunction include detailed menstrual history, physical 
and gynecological examination, basal temperature measurements, ultrasound, serum 
progesterone level and endometrial biopsy [11].   
Ovarian reserve 
Ovarian reserve describes reproductive potential as a function of the number and 
quality of oocytes [10]. It reflects the number of oocytes remaining in the ovaries that 
influences the probability of getting pregnant [7]. Decreased or diminished ovarian 
reserve (DOR) describes women of reproductive age having regular menses whose 
response to ovarian stimulation or fecundity is reduced compared with those women of 
comparable age [7].  
Diagnostic criteria for DOR is poorly defined as standardized definition is lacking 
[10, 40]. Definition and diagnostics criteria of DOR varies across fertility clinics and 
studies [40]. Evidence suggest an upward trend in the prevalence of DOR among assisted 
reproductive technology (ART) patients [41, 42]. Devin et al. reported an increase in the 
prevalence of DOR from 19 to 26% from 2004 to 2011 in a retrospective study of 
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181,536 ART cycles reported to Society for Assisted Reproductive Technologies (SART) 
by United States clinics [41]. In a cross-sectional study using ART cycles between 2004–
2007, a significant secular trend of increased odds of DOR diagnosis was observed [42]. 
The adjusted odds ratio of DOR per year studied was 1.11 (95% CI: 1.09–1.13), which 
translates to a 23% higher odd of DOR in 2005 compared to 2004, 37% higher odds of 
DOR in 2006 compared to 2004, and 52% higher odds of DOR in 2007 compared to 
2004 [42]. 
Measures of the ovarian reserve have been used to predict DOR and counsel 
infertile couples on choice of treatment [7, 10]. Tests of ovarian reserve include early 
follicular phase antral follicle count (AFC) using transvaginal ultrasonography and 
biochemical tests [7, 10, 11]. The biochemical tests include basal measurements of 
follicle-stimulating hormone (FSH), estradiol, inhibin B, and antimullerian hormone 
(AMH), and the clomiphene citrate challenge test (CCCT) [7, 10, 11]. Antral follicle 
count and serum AMH have good predictive value and are the preferred methods for 
assessing ovarian reserve [43-45].  
Antimullerian Hormone (AMH) 
Anti-Müllerian hormone (AMH), also called Müllerian inhibiting substance 
(MIS), is a glycoprotein hormone belonging to the large family of transforming growth 
factors-β (TGF- β) [10]. In women, AMH is expressed uniquely by the ovary in the 
granulosa cells, primarily secreted by primary, preantral and antral follicles and are direct 
measures of the follicular pool [10, 11]. As the number of ovarian follicles declines with 
age, AMH concentrations decline [16].  Serum concentrations of AMH are gonadotropin-
independent and therefore remain relatively constant within and between menstrual 
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cycles in both normal, young, ovulating women and in women with infertility, making it 
a valuable and reliable marker of ovarian function [10, 14, 46-48].  
The following are considered the lower limit of age-appropriate serum AMH 
values for these 5-year age intervals: 0.5ng/ML for 45 years, 1ng/mL for 40 years, 
1.5ng/mL for 35 years, 2.5ng/mL for 30 years and 3.0ng/mL for 25 years [44]. Thus, 
AMH level ≥ 1.0ng/mL but ≤3.5ng/mL if age appropriate is consistent with normal 
ovarian response to ovarian stimulation. Lower serum AMH levels(<1ng/mL) have been 
associated with poor responses to ovarian stimulation, poor embryo quality and poor 
pregnancy outcomes in IVF patients [13, 15, 49-51]. 
Varying levels of serum AMH have been used to predict ovarian response to 
stimulation. Serum cut-points ranging from 0.2 to 0.7ng/ml have been associated with 
poor ovarian response with sensitivity and specificity ranging from 40-97% and 78-92%, 
respectively [10]. In a retrospective study of one hundred and eight IVF patients, AMH 
with a cutoff of 0.2 ng/mL predicted poor response to ovarian stimulation with a 
sensitivity of 87% and specificity of 64% [51]. In a prospective study of one hundred 
thirty-five women undergoing the first cycle of assisted reproduction treatment (ART), 
serum AMH predicted poor ovarian response with a sensitivity of 100% and specificity 
of 73% at an optimum cutoff value of ≤0.99ng/mL [45]. In a meta-analysis that included 
28 studies, AMH was found to have good predictive value for poor ovarian response with 
an area under the curve (AUC) of 0.78 [52].  
Antral Follicle Count (AFC) 
Antral follicle count (AFC) is the sum of antral follicles in both ovaries, as 
observed with transvaginal ultrasonography during early follicular phase (day 2-4) of the 
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menstrual cycle [11, 44]. Antral follicles are defined as those measuring 2-10mm in mean 
diameter in the greatest two-dimensional plane [11, 44].  The AFC correlates with 
histologically determined number of primordial follicles and capacity of the ovary to 
produce oocytes in either an assisted reproduction setting or through natural 
folliculogenesis [53]. In experienced centers, AFC has good inter-cycle reliability and 
inter-observer reliability [11, 44].  
Low AFC, considered to be less than or equal 6 total antral follicles, is associated 
with poor response to ovarian stimulation during IVF [11, 44, 54]. AFC ≤10 predicted 
poor ovarian response with sensitivity of 93% and specificity of 88% with an AUC of 
0.935 in prospective study of one hundred thirty-five women undergoing the first cycle 
ART [45]. AUC for AFC in predicting poor ovarian response was found to be 0.76 in a 
meta-analysis of 28 studies on IVF [52].  
Studies have shown that AFC is highly correlated with AMH level [55, 56].  
Antral follicles measuring <6mm express the greatest amount of AMH, and levels decline 
as antral follicles increase in size [57]. Both AFC and AMH have strong and similar 
linear relationship with the size of the primordial follicle pool and ovarian reserve [43-45, 
58]. The limited intra- and inter-cycle variation, objectivity and potential standardization 
of AMH assays, makes it the preferred biomarker of ovarian reserve in women. 
Predictors/ Determinants of Ovarian reserve 
Current age and Age at menarche. Older women and women with earlier age at 
menarche have been shown to have lower levels of AMH reflecting a decline in the 
ovarian pool [12, 16]. In a cross-sectional study of premenopausal women conducted by 
Jung et al., women 40 years and older had significantly lower AMH concentrations 
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(0.73ng/ml) compared to women less than 35 years of age (2.52ng/ml) [12]. AMH 
concentrations were also significantly lower among women with age at menarche less 
than 12years (0.90 ng/mL) compared to women with age at menarche ≥14 years (1.12 
ng/mL) [12]. 
Race/ethnicity.  The association of race/ethnicity with AMH levels is 
inconsistent. In the multi-ethnic cohort study of ovarian aging (OVA), mean AMH levels 
were significantly lower in AA women (22.8±1.7pM) compared to Caucasians (30.1± 
1.5pM) [16]. The rate of decrease in level of AMH also varied by race. In Caucasian 
women, AMH decreased by 2 pM per year, while in African American women it 
decreased by 0.84 pM per year [16]. Studies that reported no association between race 
and AMH levels were cross-sectional and majorly of single ethnic group (Asian and 
Caucasian) with under-representation of other races [12, 59, 60]. 
Parity.   High parity has been postulated to have a protective effect on ovarian 
reserve by reducing follicular recruitment [61].  In cross-sectional study of 2320 women 
aged 20 to 59 years, high parity was found to be associated with higher age-specific 
AMH levels(p=0.02) [59]. Not all studies found a positive association between parity and 
AMH levels. Bragg et al. found a statistically significant inverse association between 
parity and AMH: women with 2 (p< 0.005) or 3 or more(p<0.01) children had lower 
AMH levels than nulliparous women [62]. Bleil et al. also found having had one or more 
live births versus being nulliparous was associated with a 31.1% (95% CI: 21.6%, 39.5%) 
reduction in AMH [61]. 
Oral contraceptive pill (OCP) use. Current use of OCP has been linked with 
lower levels of AMH [12, 59]. Concentrations of AMH were significantly lower among 
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current users of oral contraceptives (0.36ng/ml) compared with never or former users 
(1.15 ng/mL) [12]. 
Polycystic Ovarian Syndrome (PCOS).  Multiple epidemiological investigations 
have consistently demonstrated that women with diagnosis of PCOS have significantly 
elevated serum AMH levels. In a hospital-based case-control study, mean serum AMH 
level was markedly increased in the PCOS group (47.1 +/- 22.9 compared to. 20.8 +/- 
11.6 pmol/liter in controls; p < 0.0001) [63]. In a retrospective study of women evaluated 
for infertility, 97% of women with AMH >10ng/ml had PCOS [64]. 
Past Ovarian Surgery. Ovarian surgery is associated with decreased ovarian 
reserve possibly due to decrease in ovarian volume [65, 66]. In women with regular 
cycle, serum AMH was undetectable after bilateral oophorectomy [67]. Similarly, serum 
AMH levels were significantly decreased after 1-week post-cystectomy (median =0.67; 
range= 0.02–1.93; 95% CI: 0.44–1.70 ng/mL), and subsequently increased to about 65% 
of the preoperative level after 3 months (1.50; range=0.58–3.27; 95% CI: 0.58–3.26 
ng/mL) [65].  
Obesity. The effect of obesity, body mass index (BMI) of at least 30kg/m2, on 
ovarian reserve is inconsistent among studies. In a population-based cohort of one 
hundred and twenty-two late reproductive-age (35-47 years) women, a significant inverse 
association of AMH levels with BMI was observed [68]. Obese women had mean AMH 
levels that were 65% lower than non-obese women (geometric mean ratio (GMR) = 0.35; 
95% CI: 0.13, 0.92; p=0.034) [68]. Among ovulatory women ages 18 to 35 years, AMH 
levels were 34% lower in the obese group (2.9±2.1 ng/mL) compared to normal group 
(4.4±1.8ng/ml), p<0.05 [69]. Buyuk et al. found a similar inverse association between 
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BMI and AMH but only among women with DOR [70]. Among women with DOR, 
overweight and obese women had 33% lower AMH levels than those with a normal BMI 
(0.4 ± 0.3 vs. 0.6 ± 0.5, respectively; p=0.0001); no association was found between BMI 
and AMH among women with normal ovarian reserve [70]. The negative association 
between BMI and AMH was not replicated in other studies [59, 71-73]. 
Active smoking 
Exposure to tobacco smoke has been associated with harmful reproduction 
ranging from decreased ovarian reserve and infertility to poor pregnancy outcome [17-
19]. Some of the constituents of tobacco smoke known to have toxic effects on 
reproductive health include, carbon monoxide, nicotine, cadmium and polycyclic 
aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (B[a]P) [74, 75].  
Most of the evidence on probable biological mechanism on how exposure to 
tobacco smoke may influence ovarian reserve and reproduction is based on experimental 
studies in animals. Some of the proposed biological mechanism through which tobacco 
smoke influences ovarian reserve includes inhibition of follicular development; 
premature luteinization of the preovulatory follicle; reduction of oocyte vascularization 
and maturation; atresia of oocytes in primordial and small primary follicles; impaired 
steroidogenesis; increased chromosomal errors; and cytotoxicity [75, 76]. 
Benzo[a]pyrene (B[a]P), present in cigarette smoke, has been shown to significantly affect 
the phase I enzymes and cell death genes during preantral/antral and preovulatory growth 
leading to apoptosis and decreased viability [77]. Benzo[a]pyrene exposure decreased 
AMH output overall during preantral and antral follicle development further confirming 
the adverse effects of cigarette smoking on follicular development and survival [78]. 
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Cadmium, found in tobacco smoke, accumulates in ovarian follicles and inhibits 
the expression of P450scc leading to impaired ovarian steroidogenesis [79-81]. Cadmium 
was also shown to increase ovarian oxidative stress [82]. Increased lipid peroxidation, 
reduced glutathione contents, increased catalase activity and decreased superoxide 
dismutase activity were observed in ovaries exposed to cadmium [82]. 
Smokers have been shown to secrete significantly higher amounts of vascular 
endothelial growth factor (VEGF) soluble receptor 1, which may result in decreased 
availability of VEGF and impaired angiogenesis and oocyte maturation [83].  
Based on data from the National Health Interview Survey (NHIS), 13.6% of U.S. 
women 18 years and above were a current cigarette smoker in 2015 [84]. The prevalence 
of cigarette smoking was higher among non-Hispanic white (16.0%) followed by African 
–Americans (13.3%) and Hispanics (7.1%) [84]. In Kentucky, 24% of women 18 years 
and older were a current smoker in 2016 [85]. 
Biomarkers of Active smoking 
Cotinine is a major proximate metabolite of nicotine and reflects exposure to other 
constituents of tobacco smoke. It is measured in plasma, saliva and urine with a half-life 
ranging from 7-40 hours in adults, reflecting up to 3-5 days of exposure to tobacco smoke 
[86-88]. Urinary cotinine is a widely used biomarker of exposure to tobacco smoke. The 
advantages of urinary cotinine as biomarker of tobacco smoke exposure are that cotinine 
concentrations and other metabolites are higher than in other biological fluids; it represents 
relatively acute exposure; and collection is non-invasive [87]. The urinary cut-off of greater 
than or equal to 2.47ng/ml have been shown to detect active smoking with the highest 
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sensitivity and specificity of 100% [89]. Table 1 gives a breakdown of various cut-off 
values of urinary cotinine for smoking using receiver operating curve (ROC) [89]. 
Table 1: Varying urinary-cotinine cut-points  
Urinary cotinine (ng/ml) Sensitivity 1-specificity 
 ≥2.47 1.000 1.000 
≥12.54 0.909 0.902 
≥20.91 0.682 0.843 
≥50.59 0.500 0.588 
≥94.34 0.455 0.549 
≥105.56 0.455 0.539 
 
Levels of cotinine in urine and blood are highly correlated, with urine to blood 
ratio of 5(correlation coefficient=0.78,95%CI: 0.61 to 0.88) [90]. Levels of serum 
cotinine used to distinguish between active cigarette smoking and exposure to 
secondhand smoke (SHS) vary by study (table 2).  Levels greater than 10 ng/ml have 
been associated with recent active smoking while levels between 0.05- 10ng/ml indicates 
a SHS exposure in a non-smoker [91]. Another example of cut-points used to 
differentiate between active smoking and exposure to SHS and nonsmoking are cotinine 
levels of ≥14 ng/mL, 0.5–13.9 ng/mL, and <0.5ng/ml, respectively [88]. An optimal cut-
point determined using NHANES data (1999-2004) for distinguishing smokers from non-
smoker was 3ng/ml [92].  Recommended evaluation of cut- points by the authors differ 
by race/ethnicity: 6ng/ml, for African-American, 5ng/ml for non-Hispanic whites and 
1ng/ml for Mexican American [92]. The variations in cut-points are due to differences in 
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Smoking and Ovarian reserve 
The association of smoking with ovarian reserve have been largely inconsistent. 
Of the thirteen epidemiological studies that have explored the association of smoking 
with ovarian reserve, only eight found a significant association. Of the thirteen studies, 
only one used the biomarker cotinine to validate smoking status among participants [20].  
Fuentes et al. in a prospective cohort study examined the association between 
cigarette smoking and AMH concentrations in follicular fluid of fifty-six women 
undergoing first ART cycle [20]. Smoking status was based on follicular cotinine level 
and self-report. Women with cotinine concentrations >0.25 ng/mL in the follicular fluid 
were considered cotinine positive otherwise subjects were classified as cotinine negative. 
Participants were also categorized into current smokers, ex-smokers, and never smokers 
based on response to the smoking questionnaire. The mean concentration of AMH in 
follicular fluid was significantly decreased in the cotinine positive group compared to the 
cotinine negative group (1.02 ± 0.14 and 1.74 ± 0.15, respectively, p < 0.05) [20]. 
Similarly, current smokers had significantly lower mean AMH level (0.90 ± 0.08 ng/ml) 
compared to ex-smokers (2.00 ± 0.23 ng/ml) and never smokers (1.68 ±0.18 ng/ml) [20].  
A similar association was also found by the author in a follow up study of 141 infertile 
women [93]. Active smoking was significantly associated with a 2.29ng/mL decrease in 
plasma AMH levels (p<0.001) [93].  
Another prospective study of 277 women undergoing IVF found decreased levels 
of basal serum AMH among smokers compared to non-smokers (3.57 ± 1.74 vs. 4.34 ± 
1.91). In addition, among women that received antagonist ovarian stimulation protocol, 
smokers had significantly lower AMH levels (2.86 ± 1.32µg/l) compared to non-smokers 
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(3.74 ± 1.69 µg/l) [21]. Smoking status was based on self-report and women that quit for 
more than a year were considered non-smokers. 
Schuh-Huerta et al. prospectively examined the effects of environmental or 
lifestyle factors including self-reported smoking status on AMH levels among multi-
ethnic cohort of women aged 25 – 45 years [16]. An inverse association between 
smoking and AMH levels was found. After controlling for age, serum AMH levels were 
significantly higher among smoking women (33.5 ± 2.4) compared to non-smoking 
women (27.4 ± 1.7 pM) (p = 0.038) [16]. The mean AMH level was found to be 
significantly lower (p<0.001) in African-American women compared to Caucasians. 
Mean AMH level was 30.1 ± 1.5 pM in Caucasians and 22.8 ± 1.7 pM in African -
Americans [16]. 
Self-reported active smoking was found to be associated with a lower serum 
AMH concentrations in a retrospective analysis of IVF patients. Serum AMH 
concentrations were significantly lower in the smoker group (3.06 +/- 1.68 µg/l) 
compared to non-smokers (3.86 +/- 1.92 µg/l) after controlling for age and BMI [17]. In 
addition, serum AMH level was negatively correlated with the number of cigarettes 
smoked daily (r = −0.36, p < 0.001) [17].   
In a cross-sectional study of 284 women aged 38 to 50 years an association 
between current smoking and lower AMH levels was observed [94]. Based of 
questionnaire response, women were classified as current smokers; past smokers-reported 
a history of smoking, with cessation occurring at least 2 years before the study; passive 
smokers-currently living with someone who smoked in their home or never smokers. 
Only current smoking was associated with lower AMH values. Current smokers had 44% 
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lower AMH values than Never smokers (p = 0.04) [94]. However, the impact of smoking 
on AMH values was not dose dependent based on cigarettes per day (p = 0.08) or pack-
years (p = 0.22) [94]. 
Caserta et al. in a cross-section of 296 infertile women observed a significantly 
reduced AFC among women who reported current smoking (p = 0.04) [22]. In addition, a 
negative correlation was found between AFC and number of pack-years (r = -0.32, p = 
0.001) [22]. 
White et al. found similar inverse association of smoking with measures of 
ovarian reserve in a cross-section of 913 premenopausal women enrolled in the Sister 
study cohort [95]. Current heavy smoking, defined as smoking 20 or more cigarettes per 
day, was associated with reduced AMH (−55.3%, 95% CI: −79.8, −0.9) [95]. Among 
women who are 48 years and younger, both heavy smoking (−71.4%, 95% CI: −87.9, 
−32.4) and high pack-years (−63.4%, 95% CI: −83.5, −18.7) was associated with reduced 
AMH in current smokers [95]. 
Not all studies found an association between active smoking and AMH levels. In 
a prospective study of 136 normo-ovulatory women undergoing infertility work-up, 
median plasma AMH concentrations and AFC were not significantly different between 
self-reported smokers and nonsmokers [55]. In a multiple regression analysis adjusting 
for age smoking was not significantly association with either AMH (p=0.41) or AFC 
(p=0.34) [55].  
In a retrospective data analysis on the effect of previous or current cigarette 
smoking on risk of premature ovarian failure, there was no statistically significant 
difference in mean serum AMH concentration between the smoking categories (current, 
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ex-smoker and non-smoker) after adjustment for age (p-value 0.895) [96]. Hawkins 
Bressler et al. in cross-sectional study of 1654 African-American women aged 23-34 
found no association between self-reported active smoking and serum AMH 
concentrations [97]. In two other cross-sectional studies of premenopausal women, 
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A strong association between active smoking and ovarian reserve has not been 
established due to inconsistency in available data. Prior studies have been limited by 
small sample size [20], adjustment for a limited number of possible confounders [16, 17, 
20, 22, 55, 93, 94, 96, 98] and use of self-report to assess exposure [12, 16, 17, 21, 22, 
55, 93-98]. The categorization of smoking status also varied across the studies. Definition 
of smoking status was not explicitly stated [12, 16, 17, 21, 22, 55, 96] and assessment of 
smoking status was based on three [12, 20, 94-98] or two categories [16, 17, 21, 22, 55, 
93] (e.g., never/past/current or never/ever) which did not consider the duration and 
quantity of smoking. The few studies that explored dose-response relationship between 
smoking and ovarian reserve assessed dose using number of cigarettes smoked [59, 95, 
97], duration of smoking in years [95, 97] and pack-years of smoking [22, 59, 95]. 
N-acetyltransferase 2 (NAT2) 
N-acetyltransferase 2 (NAT2) is a polymorphic phase 2 metabolic enzyme that 
conjugates hydrazine derivatives and aromatic amine drugs with acetyl-groups [25, 99]. 
NAT2 is expressed primarily in the liver and gastrointestinal tract and involved in the 
acetylation and metabolism of some procarcinogens and xenobiotics [25, 26, 29, 100, 
101]. The NAT2 enzyme plays important roles in the metabolic activation and 
deactivation of carcinogenic aromatic amine, 4-aminobiphenyl (ABP), found in cigarette 
smoke [25, 102]. Studies of human 4-ABP exposure reported higher levels of 4-ABP-
DNA adducts that initiate mutagenesis and carcinogenesis [103], in smokers than 
nonsmoker in tissues such as larynx [104], liver [105], bladder [106, 107], breast [108-
111] and sputum [112].  The role of 4-ABP-DNA adducts and their relationship with 
tobacco exposure and ovarian reserve is yet to be evaluated. DNA adducts are a function 
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of the environmental exposure and polymorphisms in genes involved in carcinogen 
metabolism [113]. 
Polymorphisms in the NAT2 gene results in biological differences in acetylating 
capacity and metabolism that form the basis for slow, intermediate, and rapid acetylator 
phenotypes [99-101, 114]. Various combinations of single nucleotide polymorphisms 
(SNPs) on the NAT2 gene are identified as NAT2 alleles or haplotypes and many NAT2 
alleles have been identified in human populations [100, 115]. The NAT2*4 allele 
considered the “wild-type” allele due to absence of SNPs, is associated with rapid 
acetylation activity [26, 29, 114]. The NAT2 alleles containing the rs1801279 (191G>A), 
rs1801280 (341T>C), rs1799930 (590G>A), and rs1799931 (857G>A) SNPs are 
associated with slow acetylation [29, 114, 116]. The most common slow acetylator alleles 
in human populations contain one or more of these polymorphisms, identified as 
NAT2*5, NAT2*6, NAT2*7, and NAT2*14 and their subtypes [26]. Individuals 
homozygous for “wild-type” NAT2 acetylator alleles are deduced as rapid acetylators, 
individuals homozygous for slow acetylator NAT2 alleles are deduced as slow 
acetylators, and individuals possessing one rapid and one slow NAT2 allele are deduced 
as intermediate acetylators [29, 114, 117].   
Ethnic differences in the frequency of rapid and slow acetylator NAT2 alleles or 
haplotype have been reported [24, 26, 29, 118-120]. The wild-type allele occurs at 
somewhat higher frequency (41-65%) in African Americans than in non-Hispanic whites 
(20-46%) [24, 26, 121]. The slow acetylator alleles occur in about 40-60% of non-
Hispanic white population and African Americans [24, 26, 118, 120, 121]. The ethnic 
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disparity in NAT2 acetylator status is attributed to ethnic differences in the frequencies of 
SNPs and genotypes [29]. 
Variable reductions in catalytic activity, substrate affinity, and stability of NAT2 
protein expressed in human liver from individuals with slow acetylator phenotype have 
been reported [29, 100, 101, 114, 122]. Slow NAT2 acetylators have been shown to have 
higher serum concentrations of drugs and other xenobiotics, and increased susceptibility 
to adverse drug reactions and effects of toxins including those found in tobacco smoke 
[25, 26, 100, 101, 114]. 
Epidemiological studies have explored the association of NAT2 polymorphism 
with risk of various cancers such as urinary bladder [27, 29, 123-125], colorectal [126], 
lung [127], cervical [28], breast [128, 129] and ovarian [130]. NAT2 acetylator status also 
modified the association of smoking with risk of bladder and breast cancer, and colorectal 
adenoma [27, 125, 126, 128]. The presence of slow acetylation increased the bladder 
cancer risk in smokers (OR, 1.51; 95% CI, 1.34-1.70; p < .00001) in a fixed-effect model 
including 9 studies (3412 cases (663 nonsmokers and 2749 smokers) and 3507 controls 
(1413 nonsmokers and 2094 smokers)) [27]. In postmenopausal slow acetylators, current 
and past smoking increased breast cancer risk in a dose-dependent manner [128]. The 
adjusted odds ratio for smoking ≤15, 16 to 20 and more than 20 cigarettes in past 2 years 
were 0.8 (95% CI:0.3-2.5), 3.2 (95% CI:1.3-7.8),4.4 (95% CI:1.3-14.8), respectively (p-
trend, <0.01) [128]. Additionally, packs per average year significantly elevated breast 
cancer risk among postmenopausal slow acetylators (OR,2.8; 95% CI: 1.4-5.5) [128]. 
Only a handful of studies have assessed the effects of NAT2 acetylators on 
fertility and related outcomes in women. Mendola et al. in a case-control study (29 cases 
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and 72 controls) investigated the effect of smoking, NAT2 genotype and their interaction 
on recurrent spontaneous abortion in women. The odds ratio for recurrent spontaneous 
abortion was 1.34 (95% CI: 0.63 - 2.86) among smokers and 1.34 (95% CI: 0.56 - 2.54) 
among slow acetylators [131]. No significant interaction was observed. A positive 
association between slow acetylator status and endometriosis was reported in case-control 
study (29 cases and 72 controls) conducted in France [132]. In a prospective study of 319 
women office workers followed for an average of 8 menstrual cycles, NAT2 acetylator 
status modified the effect of smoking on fecundability [24]. Current smoking was 
significantly associated with reduced fecundability among slow acetylators, with an 
adjusted fecundability odds ratio of 0.34 (95% CI: 0.22 – 0.90) [24]. 
 
Summary and Gap in Current Knowledge 
Genetic heterogeneity is one factor that may explain the inconsistent results of 
previous studies on the association of smoking with ovarian reserve. NAT2 acetylator 
status have been shown to modify the association of smoking with different disease 
outcomes, with slow acetylators being more susceptible [23, 24, 27, 125, 126, 131]. 
Taylor et al. reported reduced fecundability among current smokers who are slow 
acetylators [24]; however, it remains to be established if the interaction of NAT2 
genotype and smoking on fecundability is modulated through reduction in ovarian 
reserve. No studies have assessed the effect of NAT2 acetylator status or its’ potential 
interaction with smoking on ovarian reserve. 
African- American women have lower ovarian reserve as measured by AMH levels, 
than NHW women, a finding that has been attributed primarily to genetic variations [16]. 
However, life style factor such as smoking appears to play a significant role, but to date 
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there have been no well-designed studies to address this issue. It is unclear to what extent 
ethnicity may interact with smoking to affect ovarian reserve. None of the studies on the 
association of smoking with ovarian reserve evaluated racial differences; most of the 
studies were restricted to a single ethnic group. Only a handful included NHW and AA 
participants; however, racial disparity in association of smoking with AMH were not 
evaluated.  
This study will not only add to the body of evidence on the relationship between 
smoking and ovarian reserve, it will provide evidence-based information about the 
magnitude and reliability of associations between active smoking and ovarian reserve with 
better validation of exposure using cotinine measurement.  
Findings from this study will contribute to the understanding of the racial disparity 
in ovarian reserve and how environmental/behavioral risk factors and genetic susceptibility 
may interact to reduce a woman’s ovarian reserve, impacting her reproductive potential. 
Findings will also provide evidence to support smoking cessation and policies to reduce 




D. RESEARCH DESIGN AND METHODS 
 
Study Design 
Given the uncertainty as to the relationship of smoking with ovarian reserve and 
the possibility for a long latency period, a cross-sectional study nested within the ongoing 
Louisville Tobacco Smoke Exposure, Genetic Susceptibility & Infertility Study (LOUSSI 
study) was used. This study design allowed comparison of the prevalence of smoking 
among women with diminished ovarian and women with normal ovarian reserve, 
estimation of the association of smoking with ovarian reserve and evaluation of the 
interaction of smoking with race/ethnicity and NAT2 genotype. Other possible risk factors 
were also evaluated in relation to ovarian reserve. 
The cross-sectional study design offered the advantage of a shorter study duration, 
no loss to follow and reduce cost. This is especially important, as little is known about the 
time frame from exposure to tobacco smoke and the development of DOR.  
Study Population 
The Louisville Tobacco Smoke Exposure, Genetic Susceptibility & Infertility 
Study (LOUSSI study) is an observational study that is focused on the effects of 
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tobacco exposure and NAT2 acetylator status on ovarian reserve and IVF outcomes 
(Granting institution- Eunice Kennedy Shriver National Institute of Child Health and 
Human Development; grant number- 1R15HD087911-01; principal investigator-Dr. Kira 
Taylor). Institutional Review Board approval for this study was obtained from the 
University of Louisville, IRB number:16.0063. 
Participants were recruited from the infertility clinic at the University of 
Louisville Reproductive Endocrinology and Infertility (REI) clinic. These participants are 
women of reproductive age seeking infertility treatment and were mostly from the 
Louisville and southern Indiana area. Based on medical record data and personal 
communication with Dr. Bohler (Co-investigator on LOUSSI study), about 350 female 
patients were referred to the University of Louisville REI clinic for fertility treatment in 
2017 and approximately 55% are Non-Hispanic White, 27% Non-Hispanic Black and 
10% are Hispanic. Data from CDC Assisted Reproductive Technology (ART) report 
showed that 60% of women who used ART at the University of Louisville Fertility center 
in 2015 were less than 35 years of age [133]. 
Inclusion Criteria: All women 21 years and above seeking infertility treatment at 
the University of Louisville Reproductive Endocrinology and Infertility (REI) clinic were 
eligible for enrollment into the study. Both new and existing patients planning various 
types of fertility treatments were eligible for recruitment into the study. 
Excluded were women with ongoing pregnancy and patients who cannot 




Subject Recruitment Methods 
All clinic patients were mailed a participation letter and a brochure describing the 
study, inviting them to contact the Principal investigator if they wish to participate. In 
addition, women 21 years and older seeking fertility treatment at the REI clinic were 
approached during their visit by the attending physician to determine interest and 
eligibility for the study. Patients who express interest were referred to a research assistant 
who explains the benefits and risks of the study as well as the study procedures. Informed 
consent process (IRB number: 16.0063) was initiated for patients that agreed to 
participate and a gift card ($25) offered, to thank them for their participation. For this 
dissertation, 265 women were recruited from the REI clinic between September 2016 and 
June 2018. 
Exposure Assessment 
The primary exposure, current active smoking, was assessed based on response to 
supplemental smoking questionnaire and urinary cotinine levels. The urinary cut-point 
for discriminating smokers from nonsmokers was set at ≥100ng/mL and validity of self-
reported smoking was tested using a Kappa statistic.   
• Current smoker: - defined as a person that self-identifies as currently smoking at 
least 1 cigarette/week or quit less than 1 month ago; AND has positive cotinine 
levels (≥100 ng/mL). 
• Former smoker: - defined as a non-current smoker with history of smoking at 




• Nonsmoker: - never smoked more than 1 cigarette/week AND has cotinine levels 
<14 ng/mL. 
• Cumulative lifetime smoking: Pack-years smoked was calculated for current and 
former smokers by multiplying the number of packs smoked per day by the years 
of smoking. 
Outcome Measurement 
Assessment of ovarian reserve was based on baseline serum AMH levels. This 
measure of ovarian reserve was extracted from patients’ medical record. Women 
routinely provide a serum sample for analysis of reproductive hormones, including AMH 
as part of the initial infertility workup, and have transvaginal ultrasound performed to 
assess follicular development and count antral follicles. The AMH assays were performed 
by Quest Diagnostics using chemiluminescence with lower limit of detection being 
0.03ng/mL. AMH value below the lower limit of detection was assigned a value of 
0.03ng/mL.  
The cut-points of AMH for diagnosis of DOR range from 0.1 to over 2.5ng/ml 
[10, 48, 49]. For this study, diminished ovarian reserve (DOR) was defined as having 
baseline serum AMH level less than 1ng/mL [97, 134]. 
NAT2 Acetylator Status 
Four SNPs, rs1801279 (191G>A), rs1801280 (341T>C), rs1799930 (590G>A), 
and rs1799931 (857G>A) in the NAT2 coding region and their corresponding alleles and 
haplotypes were determined [29]. NAT2 variants for these SNPs are associated with slow 
acetylation [29]. The NAT2*4 allele is associated with rapid acetylation activity [29]. 
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• Rapid acetylators: defined as possessing two of the NAT2 alleles associated 
with rapid acetylation activity (NAT2*4) 
• Intermediate acetylators: defined as possessing one of the alleles associated 
with rapid acetylation activity and one allele associated with slow acetylation 
(NAT2*5, NAT2*6, NAT2*7, and NAT2*14). 
• Slow acetylators: individuals that possessed two slow acetylation alleles 
(NAT2*5, NAT2*6, NAT2*7, and NAT2*14) were classified as slow acetylators. 
Covariates 
The covariates assessed include but are not limited to sociodemographic 
characteristics (age, ethnicity); marital status; weight and height at enrollment for 
calculation of body mass index (BMI); age at menarche, parity and PCOS status. Age, 
ethnicity, marital status, age at menarche and parity was based on self-report. PCOS 
status was based on self-report or physician diagnosis.  
BMI at enrollment, calculated as the body weight in kilograms divided by the 
square of height in meters (kg/m2) was used to classify participants as normal weight 
(17.5 – 24.9), overweight (25.0 – 29.9), obese (30.0 – 34.9), or morbidly obese (≥35) 
based on WHO classification [135]. 
Data Collection and Study Procedures 
Exposure to tobacco smoke was assessed using a combination of a self-
administered smoking questionnaire (SSQ; appendix 1) and cotinine levels in urine. The 
SSQ was administered during subject’s clinic visit. Urine sample was also collected for 
cotinine assay and DNA extraction, after informed consent was signed.  Information on 
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outcome measures and covariates were extracted from medical record (data collection 
form; appendix 2).  
Medical record excerpts, biological specimens (urine and DNA samples) and 
questionnaires were labeled with an identification number randomly assigned to each 
participant. The newly assigned identification number was used to create and populate an 
electronic database with data from medical records, SSQ, cotinine and NAT2 assays. 
1. Instrument: Self-administered Smoking Questionnaire (SSQ) 
Once a participant has agreed to partake in the study and signed informed consent 
form, a self-administered SSQ designed to assess active and passive exposure to tobacco 
smoke was given to subject. 
Quality control: Questions from the smoking questionnaire (SSQ) were adapted from 
smoking questions from National Health and Nutrition Examination Survey III 
(NHANES III) and National Health interview survey [136, 137]. 
2. Medical Record Extraction 
Information on the outcome measure and important covariates were extracted 
from the patient history form (appendix 3) and medical record using data collection 
sheets labeled with the patient’s randomly assigned identification number. 
The patient history form is a survey completed by patients at first clinic visit. The 
survey is designed to collect information on demographic characteristics, reproductive 
and social history.  Data extracted were selected based on the relationship to fertility 
outcomes, tobacco smoke exposure, or both. Information assessed from the patient 
history form include but are not limited to, date of visit; sociodemographic characteristics 
(age, ethnicity); menstrual history (age at first period, menstrual cycle length and 
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regularity, ovulation); number of previous pregnancies; sexually transmitted infections; 
social history (occupation, marital status and length of time with current partner); 
physical exercise and diet history; alcohol and caffeine use; and smoking history. 
The racial categories noted on the patient history form include American Indian; 
Asian; White; Alaska Native; Black or African American; Native Hawaiian or other 
Pacific Islander; and other. For ethnicity, patient can self-identify as Hispanic/ Latino or 
not Hispanic/Latino. 
Information on AMH which is routinely done as part of infertility workup was 
extracted from the medical record as well as PCOS diagnosis. Results of AMH assay 
done after first clinic visit (for new patients) and within six months of enrollment (for 
existing patients) was extracted. Physical measurements (weight, height, BMI and blood 
pressure) taken at time of enrollment was also assessed from the medical record. 
Quality control: Medical records were extracted in duplicate and updated as study 
progressed.  
3. Cotinine Assays 
Cotinine, a biomarker of tobacco use, is a major metabolite of nicotine and can be 
detected in urine and other bodily fluids for up to 72 hours following exposure [88].  
Urine was collected at enrollment (during the patient’s office visit) into sterile 
vials and labeled with the patient’s randomly assigned identification number. Urine 
samples were divided into two; one for the cotinine assays and the other for DNA 
extraction. The samples were stored at 4 degrees Celsius until time of assay. DNA 
samples were frozen at -20 degrees Celsius until genotyping. 
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Cotinine ELISA assays (Calbiotech, Spring Valley, CA) was used be used to 
estimate the level of cotinine in the urine of participants. The Calbiotech Cotinine kit is a 
solid phase competitive ELISA that contain standards and controls. Cotinine in the 
samples competes with a cotinine enzyme (HRP) conjugate for binding sites. The 
intensity of color generated at the end of assay procedure is inversely proportional to the 
concentration of cotinine in the samples. A standard curve was then prepared relating 
color intensity to the concentration of the cotinine. The maximum detectable level of 
cotinine for the Calbiotech assay is 100ng/mL. Urinary cotinine levels were estimated to 
the nearest 0.50ng/mL. 
Quality control: All cotinine assays were done in triplicate and mean value was used. 
Samples with relative standard deviation greater than 0.10 were assayed in triplicate a 
second time in a subsequent assay. 
4. NAT2 Assays 
Genomic DNA was isolated from urine sample using the ZR Urine DNA Isolation 
Kit™ (Zymo Research, Irvine, CA. USA) according to manufacturer’s instructions. A 
NAT2 four-SNP genotype panel of rs1801279 (191G>A), rs1801280 (341T>C), 
rs1799930 (590G>A) and rs1799931 (857G>A) was used to infer NAT2 acetylator 
phenotype. The accuracy of the four-SNP panel in determining NAT2 acetylator status is 
98.4% and comparable to the seven-SNP panel [138]. The assay uses SNP-specific PCR 
primers and fluorogenic probes designed using Primer Express™ (Applied Biosystems, 
CA, USA). The fluorogenic probes are labeled with a reporter dye (either 
carboxyfluorescein or VIC®, Applied Biosystems) and are specific for one of the two 
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possible bases identified at the four SNPs rs1801279 (191G>A), rs1801280 (341T>C), 
rs1799930 (590G>A) and rs1799931 (857G>A) in the NAT2 coding region [139].  
The presence of the four SNPs was determined using a predeveloped TaqMan® 
SNP Genotyping Assays (Applied Biosystems) according to manufacturer’s instructions. 
Briefly the 20× primer and probe mix was used at a 1× concentration with a half volume 
of 2× TaqMan Universal PCR Master Mix and 12.0 ng of genomic sample per well [138, 
140]. Assays were designed and optimized to work with TaqMan® Universal PCR 
Master Mix using the same thermal cycling conditions, which are 60°C for 30 s, 95°C for 
10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The PCR 
amplification and end-point reading were performed on Step One Plus™ real-time 
instrument (Applied Biosystems). Major advantages of the TaqMan® SNP Genotyping 
Assays are that they do not require post-PCR processing (such as enzyme digestion) or 
the use of radioactivity [140]. 
Quality control: Controls (no DNA template) were ran to ensure that there is no 
amplification of contaminating DNA. 
Statistical Analyses 
Distribution of variables were examined; frequencies and percentages for 
categorical variables; mean and standard deviation for normally distributed continuous 
variable; median with interquartile ranges for non-normally distributed continuous 
variable. Differences in demographics and covariates between smokers and nonsmokers 
were tested using chi-square for categorical variables, Student’s T-test for continuously 




The outcome measure, baseline AMH level was not normally distributed. Two 
regression models, linear regression and logistic regression, was used to examine the 
relationship between active exposure to tobacco smoke and ovarian reserve. 
Linear regression models with natural logarithm(ln) of AMH as the dependent 
variable was used to generate adjusted estimates of β associated with each exposure of 
interest. Percent differences and 95% confidence intervals (CIs) in serum AMH between 
exposure groups was calculated from the βs as follows; ([exp(β) −1] *100) and presented 
with corresponding 95% confidence intervals (CIs) and p-values [97]. Multivariable-
adjusted logistic regression was used to assess odds of diminished ovarian reserve 
(DOR), defined as AMH <1ng/mL, and 95% CIs. 
Confounders were evaluated using a combination of theory and data-based 
approach. Adjustment were made for known covariates such as age, race/ethnicity, BMI, 
age at menarche parity and PCOS status in multivariable regression analyses while other 
variables that change the beta estimate for exposure by more than 10 % were considered 
as confounder. In addition, regression analyses were stratified by PCOS status. 
All analyses were two-sided and conducted using Statistical Analysis Software 
version 9.4 (SAS Institute, Cary, NC). Statistical significance was assumed for p-value 
<0.05. 
Treatment of exposure variables for each of the specific aims: 
Specific aim 1(a) Current active smoking (dichotomous; yes/no): The effect of 
current active smoking on ovarian reserve was assessed by comparing current active 




Specific aim 1(b) dose-response relationship (Continuous and categorical): 
The dose of exposure for current active smoking was based on number of cigarettes 
smoked per day reported on the SSQ. The dose-response relationship between current 
active smoking and ovarian reserve was modeled as both a continuous exposure variable 
and categorical variable; 0 (nonsmoker), 1– <10 cigarettes per day vs ≥ 10 cigarettes per 
day. 
Specific aim 1(c) cumulative lifetime smoking (Continuous and categorical): 
The cumulative lifetime smoking was based on number of packs smoked per day and 
duration of smoking in years reported on the SSQ by both current active smokers and 
former smokers. The lifetime pack-years of smoking was calculated by multiplying the 
number of years reported smoking times the number of packs on average that they smoke 
per day. The effect of cumulative lifetime years of active smoking was assessed with 
both a continuous exposure variable and categorical variable using meaningful cut points. 
Specific aim 2 Race - smoking interaction: To determine if the relationship 
measured in specific aim 1a differ by race, an interaction term for race and current 
smoking status was added to the model. The association was compared among non-
Hispanic White and African-Americans for potential effect modification. Information on 
self-reported race was extracted from medical record.  
Specific aim 3 NAT2 acetylator status - smoking interaction: Intermediate and 
rapid acetylators were grouped together in the analysis because they have been shown to 
have similar acetylation activity. Rapid acetylators were compared to slow acetylators. 
NAT2, a dichotomous variable indicating slow/fast acetylator phenotype was created. 
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The interaction term for smoking*NAT2 was included into the model to assess effect 
modification.   
Model statement: 
Specific aim 1(a): 
Logistic regression: 
Log (odds of DOR) = β0+ β1*Smoking + β2*Age + β3*Race + β4*BMI+ β5*Parity+ 
β6*Age at menarche + β7*PCOS 
Linear regression: 
Ln (AMH) = β0+ β1*Smoking + β2*Age + β3*Race + β4*BMI+ β5*Parity+ β6*Age at 
menarche + β7*PCOS 
Specific aim 2: 
Logistic regression:  
Log (odds of DOR) = β0+ β1*Smoking + β2*Race + β3*Smoking*Race+ β4*Age + 
β5*BMI+ β6*Parity+ β7*Age at menarche + β8*PCOS 
Linear regression: 
Ln (AMH) = β0+ β1*Smoking + β2*Race + β3*Smoking*Race+ β4*Age + β5*BMI+ 
β6*Parity+ β7*Age at menarche + β8*PCOS 
Specific aim 3: 
Logistic regression:  
Log (odds of DOR) = β0+ β1*Smoking + β2*NAT2 + β3*Smoking*NAT2+ β4*Age + 
β5*Race+ β6*BMI +β7*Parity+ β8*Age at menarche + β9*PCOS 
42 
 
Sample Size / Power calculation 
Based on the literature review, the estimated mean difference in AMH between 
current smokers and nonsmokers ranges between 0.78- 1.1 and the sample size estimates 
generated based on these effect sizes ranged from 118 -398. 
Because parameters of diminished ovarian reserve and study population vary from 
study to study, sample size estimates and power calculations were based on preliminary 
data from the LOUSSI study. The estimated difference in mean AMH between current 
smokers and nonsmokers was 1.49ng/ml with standard deviation of 4.18ng/mL. The 
estimated age- adjusted odds ratio for DOR for smoking 1 cigarette per day was 
1.11(95% CI:1.01 – 1.21, p=0.03). The prevalence of smoking was 24% while the 
prevalence of DOR among non-smokers in this population was 30%.  
Two separate sample size calculations were performed for the main objective of 
the study, effect of smoking on ovarian reserve, using Proc power in SAS (SAS Institute, 
Cary, NC). The sample size estimates were based on statistical power of 80%, alpha= 
0.05 level of significance and ratio of smokers to nonsmokers set at 1:3. 
Table 4.1 shows sample size estimates using a standard deviation of 4.18ng/mL 
for varying mean differences in AMH when comparing smokers to nonsmokers. Sample 
size estimates for different odds ratio for DOR are presented in Table 4.2. Based on the 
Louisville Metro Behavioral Risk Factor Surveillance System, 24% of women resident in 
Louisville metro were current smoker in 2016 [141]. The prevalence of smoking 10 
cigarettes per day among the study population was assumed to be 11% and estimated 




Table 4. 1: Sample size estimate for the difference in mean AMH levels between smokers 
and nonsmokers 
Mean difference in AMH 
(ng/mL) 
Statistical power Total sample size 
1.4 0.801 376 
1.5 0.801 328 
1.6 0.800 288 
1.8 0.801 228 
2.0 0.807 188 
 
Table 4. 2: Sample size estimate for different odds ratio for effect of smoking on DOR 
Odds Ratio Statistical Power Total sample size 
2.00 0.800 524 
2.50 0.802 282 
2.84(10 cigarettes/day) 0.803 210 
3.00 0.801 186 
3.50 0.803 138 
8.06(for 1pack/day) 0.805 42 
Power for active smoking and NAT2 interaction analyses were based on 
dichotomized exposure (smoker vs. nonsmoker) and outcome, DOR. Power calculations 
were performed for anticipated sample size of 250 using a power and sample size 
program for genetic association studies and gene-environment interaction, QUANTO 
(http://biostats.usc.edu/Quanto.html). Based on data from the LOUSSI study, the 
prevalence of current smoking and DOR in this population was 24% and 30%, 
respectively. The estimated effect size for smoking and NAT2 was 1.4. Table 4.3 
44 
 
provides power estimates for minimum detectable odds ratio for smoking-NAT2 
interaction for an anticipated sample size of 250 at alpha= 0.05 level of significance. The 
sample size is further broken down by NAT2 status in Table 4.4. 
Table 4. 3: Power calculations for detecting a significant gene-environment interaction 
between active smoking and NAT2 
Anticipated sample size 
(40% slow acetylators, 60% 
Rapid/intermediate 
acetylators) 
Minimum detectable odds 
ratio for smoking-NAT2 
interaction 
Power to detect significant  
Smoking-NAT2 
interaction  
250 1.4 0.17 
250 1.6 0.28 
250 1.8 0.41 
250 2.0 0.52 
250 2.5 0.74 
 
Table 4. 4: Sample size estimate stratified by NAT2 acetylator status 





Slow acetylators 25 75 100 
Rapid/Intermediate 
acetylators 
38 112 150 






Out of 265 women who were enrolled into the LOUSSI study, 59 (22.3%) were 
excluded for the following reasons: missing medical record data on serum AMH levels 
(n=44); or they did not provide urine for cotinine assays (n=15). An additional 36 women 
were excluded from analyses due to lack of correlation between self-reported smoking 
status (never smoker or former smoker for more than 1 month) and increased cotinine 
level indicating either a high tobacco exposure (≥100ng/mL, n=16) and or significant 
passive exposure (14-99ng/mL, n=20) (Figure 1). The overall Kappa statistics of self-
reported smoking status was 0.81 (95% CI: 0.72 – 0.89; p<0.001) (data not shown). 
 The remaining 170 women included 31 (18%) current active smokers and 139 
(82%) nonsmokers.  Among the current smokers, 53% reported smoking 10 or more 
cigarettes per day, 21% reported smoking between 5 to 9 cigarettes per day while 26% 
reported smoking less than 5 cigarettes per day.  
Table 5.1 presents the characteristics of the women in the LOUSSI study stratified 
by smoking status. Nonsmokers had higher AMH levels, AFC and prevalence of DOR 
than smokers, but the differences were not significant.  In general, smokers tended to be 
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younger (P=0.04), of self-reported White race (p=0.01) and were more likely to be single 
(71% vs. 23%, p= <0.001). Smokers and nonsmokers were comparable in terms of age at 
menarche, BMI, parity and prevalence of PCOS. 
The NAT2 acetylator status of the participants is presented in Table 5.2. DNA 
extraction and/or NAT2 genotyping were unsuccessful in 14 participants. A total of 11 
NAT2 genotypes were identified and assigned to rapid, intermediate and slow. About 
39% of women in the study were slow acetylators, 44% intermediate and 17% rapid 
acetylators. Rapid and intermediate acetylators were merged for analysis. The distribution 














































Total number of women enrolled into the LOUSSI Study 
N=265 
Missing data on serum AMH 
levels (n=44) 
Sample available for analysis 
N=206 
Final sample size 
N=170 
Did not provide urine for 
cotinine assays (n=15) 
Self-reported never smokers & 
former smokers with cotinine level 
≥100ng/mL (n=16) 
Self-reported never smokers & 















 N (%) 
(n=31) 
P-value 
Age (years)   0.04 
21-25 16 (11.5) 9 (30.0)  
26-30 26 (18.7) 7 (23.3)  
31-35 50 (36.0) 8 (26.7)  
36-45 47 (33.8) 6 (20.0)  
Race    0.01 
White 73 (52.9) 17 (54.9)  
Black 32 (23.2) 13 (41.9)  
Other 33 (23.9) 1 (3.2)  
Age at menarche(years) mean (s.d) 12.5 (1.9) 11.9 (1.5) 0.10 
Body Mass Index   0.17 
17.5-24.9 36 (26.3) 8 (25.8)  
25-29.9 44 (32.1) 6 (19.4)  
30-34.9 25 (18.2) 11 (35.4)  
≥ 35 32 (23.4) 6 (19.4)  
Poly Cystic Ovary Syndrome   0.80 
No 83 (60.6) 18 (58.1)  
Yes 54 (39.4) 13 (41.9))  
Parity    
None 60 (43.8) 9 (29.0) 0.30 
One 31 (22.6) 8 (25.8)  
Two or more 46 (33.6) 14 (45.2)  
Marital Status    <0.001 
Single 31 (23.7) 20 (71.4)  
Married 100 (76.3) 8 (28.6)  
Serum AMH (ng/mL) median 
(interquartile range) 2.33 (4.0) 2.07 (2.0) 0.48 
Diminished ovarian reserve (DOR)   0.59 
No 101 (72.7) 24 (77.4)  
Yes 38 (27.3) 7 (22.6)  
Antral Follicle Count (AFC) 
median (interquartile range) 21 (17) 17(11) 0.48 
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Table 5. 2. NAT2 Phenotype of Women in the Study (N =156) 
 
Specific Aim 1 Results 
1a) Assess the association of current active smoking with ovarian reserve. 
1b) Determine a dose-response relationship between current active smoking (as 
measured by number of cigarettes smoked per day) and ovarian reserve. 
The association of current active smoking with ovarian reserve was assessed 
using linear regression with ln (AMH) as the outcome and logistic regression for DOR. 
Results from the univariate analyses are presented in Table 5.3. No statistically 
significant association was observed between current active smoking and ovarian reserve 
(AMH and DOR) (Table 5.3). Age and PCOS status were significantly associated with 
both serum AMH level and DOR.  A 50% (95% CI: -72.0 – -9.8) decrease in AMH level 
was reported among women between ages 31 to 35 years and a 64% (95% CI: -79.9 – -
35.2) decrease among women older than 35 years of age (Table 5.3). A similar inverse 
association was found between age and DOR, with women between the ages of 36 to 45 
years having 6 times the odds of DOR (OR=5.89; 95% CI:1.63 – 21.38) compared to 
women 21 to 25 years of age (Table 5.3). A PCOS diagnosis was associated with a 
significant increase in AMH levels and a decrease in the odds of DOR (Table 5.3). 
 
Rapid/ Intermediate Acetylators  
N (%) 
 (n=95) 




Smoking Status   0.91 
Smokers 18 (19.0) 12 (19.7)  
Nonsmokers 77 (81.0) 49 (80.3)  
Race   0.79 
White 51 (54.2) 31 (50.8)  
Black 23 (24.5) 18 (29.5)  
Other 20 (21.3) 12 (19.7)  
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Neither serum AMH levels nor DOR was found to be significantly associated 
with race, BMI, age at menarche or parity (Table 5.3). However, BMI category and parity 
were considered for inclusion in all multivariable models with ln (AMH) and DOR as 
outcomes because they were related to ovarian reserve at a significance level of p<0.20. 
All regression models were adjusted for age and PCOS status. 
Adjusted linear regression models for the association of current active smoking 
and percentage change in AMH are presented in Table 5.4. There was no significant 
association found between current active smoking or the number of cigarette smoked and 
AMH level (smoker vs. nonsmoker: % ∆ in AMH -5.6; 95% CI: -48.2 – 72.1) (Table 
5.4).  
After adjusting for age and PCOS status, current active smoking was not 
associated with DOR (OR=1.14; 95% CI: 0.41 – 3.18).  No dose-response relationship 
was found between number of cigarette smoked and DOR, regardless of whether the 
exposure was measured as continuous (OR=1.04; 95% CI: 0.98 – 1.10, p=0.19) or 
categorized (1– 9 cigarettes /day: OR=0.30; 95% CI: 0.03 – 2.6); ≥10 cigarettes /day: 
OR=2.02; 95% CI: 0.62 – 6.69) (Table 5.4). When analyses were limited to women 
without PCOS, the effect of current smoking on DOR was stronger but did not reach 







Table 5. 3. Univariate Analyses for the Association of Current Active Smoking with 
Percent Change in Anti -Müllerian hormone (AMH) and Risk of Diminished 
Ovarian Reserve (DOR) 
 
% Change in AMH 
(95% CI) 
OR (95% CI) for DOR 
Smoking Status   
Nonsmoker Referent 1.00 (Referent) 
Smoker -5.6 (-48.2 – 72.1) 0.78 (0.31 – 1.95) 
p-value 0.85 0.59 
Age (years)   
21-25 Referent 1.00 (Referent)a 
26-30 20.5 (-36.3 – 127.9) 0.48 (0.08 – 3.08) 
31-35 -49.7 (-72.0 – -9.8) 3.63 (0.98 – 13.39) 
36-45 -63.9 (-79.9 – -35.2) 5.89 (1.63 – 21.38) 
p-value <0.001 0.0012 
Race   
White Referent 1.00 (Referent) 
Black 11.0 ( -29.5 –75.0) 0.73 (0.34 – 1.56) 
Other -23.6 (-55.6 – 31.6) 0.98 (0.41 – 2.33) 
p-value 0.46 0.69 
Age at menarche 8.8 (-2.6 – 21.6) 0.89 (0.74 – 1.07) 
p-value 0.14 0.22 
Body Mass Index   
17.5-24.9 Referent 1.00 (Referent)b 
25-29.9 -17.2 (-51.8 –42.3) 1.64 (0.63 – 4.28) 
30-34.9 -35.0 (-63.3 – 16.1) 1.94 (0.71 – 5.28) 
≥ 35 -13.0 (-51.1 – 54.9) 2.33 (0.88 – 6.21) 
p-value 0.53 0.38 
PCOS   
No Referent 1.00 (Referent) 
Yes 173.5 (86.1 – 301.9) 0.32 (0.15 – 0.69) 
p-value <0.001 0.004 
Parity   
None Referent 1.00 (Referent)c 
One -27.3 (-55.8 – 19.8) 1.45 (0.63 – 3.34) 
Two or more -39.1 (-61.1 – -4.7) 1.25 (0.58 – 2.70) 
p-value 0.09 0.67 





Table 5. 4. Multivariable Model for Association of Current Active Smoking with 
Percent Change in Anti -Müllerian hormone (AMH) and Risk of Diminished 
Ovarian Reserve (DOR) (N=167) 
 % Change in AMH  
(95% CI) 
OR (95% CI) for DOR 
Model 1a   
Current smoking status     
Nonsmoker, n=137 Referent 1.00 (Referent) 
Smoker, n=30 -24.7 (-57.1 – 32.1) 1.14 (0.41 – 3.18) 
p-value 0.32 0.81 
Model 1b   
Number of cigarettes/day  -1.95 (-5.10 – 1.30) 1.04 (0.98 – 1.10) 
p-value 0.23 0.19 
Model 1bii   
Number of cigarettes/day (categories)    
0, n=137 Referent 1.00 (Referent) 
1-9, n=12 -9.17(-60.59 – 109.29) 0.30 (0.03 – 2.63) 
≥10, n=18 -33.42(-210 – 33.19) 2.02 (0.62 – 6.69) 
p-value 0.51 0.25 
Adjusted for age and polycystic ovary syndrome 
 
Table 5. 5. Multivariable Model for Association of Current Active Smoking with 
Percent Change in Anti -Müllerian hormone (AMH) and Risk of Diminished 
Ovarian Reserve (DOR) Among Women Without Polycystic Ovary Syndrome 
(PCOS) (N=100) 
 
 % Change in AMH  
(95% CI) 
OR (95% CI) for DOR 
Model 1a   
Current smoking status     
Nonsmoker, n=83 Referent 1.00 (Referent) 
Smoker, n=17 -10.3 (-59.94 – 100.92) 1.75 (0.49 – 6.33) 
p-value 0.79 0.39 
Model 1b   
Number of cigarettes/day  -0.75 (-4.89 – 3.58) 1.06 (0.99 – 1.14) 
p-value 0.73 0.08 
Model 1bii   
Number of cigarettes/day   
0, n=83 Referent 1.00 (Referent) 
1-9, n=7 -17.69 (-74.59 – 166.61) 0.49 (0.05 – 5.06) 
≥10, n=10 -4.76 (-65.04 – 159.46) 3.44 (0.68 – 17.31) 
p-value 0.95 0.25 
Adjusted for age 
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Specific Aim 1c- Assess a dose-response relationship between cumulative lifetime 
smoking (as measured by pack-years reported on the questionnaire) and ovarian 
reserve. 
Overall n=204 women were included in the analysis for Specific Aim 1c. 
Cumulative lifetime of smoking was assessed for both smokers and former smokers via 
questionnaire. Cumulative lifetime of smoking was not significantly associated with 
change in serum AMH levels or increased risk of DOR (Table 5.6). The association 
remained insignificant when the analysis was restricted to women without PCOS (Table 
5.7). 
Table 5. 6. Association of Cumulative Lifetime Smoking Exposure as a Continuous 










 % Change in AMH  
(95% CI) 
OR (95% CI) for DOR 
Pack-years, Continuous   
Lifetime exposure (pack-years) -1.46 (-5.70 – 2.98) 1.05 (0.97 – 1.13) 
p-value 0.51 0.24 
Pack-years, Categorical   
Never Smoker, n=149 Referent 1.00 (Referent) 
1-5, n=35 9.64 (-33.28 – 80.15) 0.65 (0.24 – 1.77) 
>5, n=20 -27.62 (-61.36 – 35.58) 1.68 (0.54 – 5.17) 
p-value 0.52 0.41 
Adjusted for age and polycystic ovary syndrome  
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Table 5. 7. Association of Cumulative Lifetime Smoking Exposure as a Continuous 
Measure and as a Categorical Measure with Percent Change in AMH and Risk of 
DOR Among Women Without Polycystic Ovary Syndrome (N=123) 
 % Change in AMH  
(95% CI) 
OR (95% CI) for DOR 
Pack-years, Continuous   
Lifetime exposure (pack-years) -1.20 (-6.37 – 4.26) 1.08 (0.99 – 1.18) 
p-value 0.66 0.08 
Pack-years, Categorical   
Never Smoker, n =92 Referent 1.00 (Referent) 
1-5, n=21 -12.78 (-55.95 – 72.67) 1.04 (0.34 – 3.18) 
>5, n=10 -7.20 (-63.52 – 136.06) 3.16 (0.68 – 14.12) 
p-value 0.92 0.32 
Adjusted for age 
 
Specific Aim 2- Determine if the association of current active smoking with ovarian 
reserve differ by race, comparing African-American with Caucasians (NHW) 
women. 
The interaction between race and current active smoking on ovarian reserve was 
assessed using logistic regression, with DOR as the main outcome. Results of the analysis 
are presented in Table 5.8. After adjusting for age and PCOS diagnosis, no significant 
interaction was found between current active smoking and race on DOR (p-value=0.91). 
Results were non-significant for women without PCOS (Table 5.9). Similarly, no 








Table 5. 8. Interaction of Current Active Smoking and Race on Risk of Diminished 
Ovarian Reserve (DOR) (N= 135) 






OR (95% CI) Sample 
size 
OR (95% CI) 
Nonsmoker 73 1.00 32 0.55 (0.20 – 1.56) 
Smoker 17 1.18 (0.30 – 4.67) 13 1.34 (0.27 – 6.86) 
P-value for 
interaction=0.91 
    
Adjusted for age and polycystic ovary syndrome  
 
Table 5. 9. Interaction of Current Active Smoking and Race on Risk of Diminished 
Ovarian Reserve (DOR) Among Women without Polycystic Ovary Syndrome 
(N=82) 
 Non-Hispanic White African-American 
 Sample 
size 
OR (95% CI) Sample 
size 
OR (95% CI) 
Nonsmoker 41 1.00 23 0.48 (0.14 – 1.64) 
Smoker 10 1.25 (0.23 – 6.82) 8 3.74 (0.50 – 27.79) 
P-value for 
interaction=0.41 
    
Adjusted for age 
 
 
Specific Aim 3- Determine interaction between current active smoking and NAT2 
acetylator status on ovarian reserve. 
The effect measure modification by NAT2 was assessed using logistic regression 
with DOR as outcome. After adjusting for age, race and PCOS status, there was no 
significant interaction with NAT2 (Table 5.10); among slow acetylators: the association 
between smoking and DOR was OR=1.63 (95% CI:0.27– 9.94); whereas in rapid 
acetylators, OR=0.89 (95% CI: 0.25 – 3.24). 
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When analysis was limited to women without PCOS, the effect modification by 
NAT2 acetylator status became stronger but did not reach statistical significance (Table 
5.11). Current active smokers who are slow acetylators had twice the odds of DOR 
(OR=2.51;95% CI: 0.15 – 42.64) (Table 5.11). 
 
Table 5. 10. Interaction of Current Active Smoking and NAT2 Acetylator Phenotype 







OR (95% CI) Sample 
size 
OR (95% CI) 
Nonsmoker 77 1.00 49 0.65 (0.26 – 1.62) 
Smoker 18 0.89 (0.25 – 3.24) 12 1.63 (0.27 – 9.94) 
P-value for 
interaction=0.29 
    
Adjusted for age, race and polycystic ovary syndrome  
 
Table 5. 11. Interaction of Current Active Smoking and NAT2 Acetylator Phenotype 
on Risk of Diminished Ovarian Reserve (DOR) Among Women Without Polycystic 







OR (95% CI) Sample 
size 
OR (95% CI) 
Nonsmoker 49 1.00 25 0.37 (0.11 – 1.14) 
Smoker 13 1.15 (0.28 – 4.76) 4 2.51 (0.15 – 42.64) 
P-value for 
interaction=0.23 
    






This study assessed the association of smoking with ovarian reserve among 
women of reproductive age. The existing evidence on smoking and ovarian reserve as 
measured by AMH has been inconclusive [12, 16, 17, 20, 21, 55, 93-98]. This is the 
first study to explore effect modification by race and NAT2 phenotype as a possible 
cause of inconsistency in previous studies, and the first study of smoking and ovarian 
reserve to validate self-reported exposure status with cotinine. 
The findings from this cross-sectional analysis are consistent with previous 
prospective [55], retrospective [96] and cross-sectional studies [12, 97, 98] that found 
no significant association between smoking and ovarian reserve. However, other 
studies did find a significant association between smoking and ovarian reserve [16, 
17, 20, 21, 93-95]. If an association truly exists, then nonsignificant results from 
previous studies may be due to a crude assessment of smoking exposure status based 
on self-report and not accounting for duration and quantity of smoking. Further, 
previous results are difficult to reconcile because of differences in the definition of 




Only a few studies have explored a dose-response relationship between smoking 
and ovarian reserve [22, 59, 95, 96]. This study provided a detailed assessment of 
smoking status, validated current exposure status with cotinine, assessed a dose-response 
relationship, and estimated cumulative lifetime exposure using the quantity and duration 
of smoking. While effect sizes did not reach statistical significance, the magnitude and 
direction of associations suggest that smoking may reduce ovarian reserve especially 
among heavy smokers. White et al. (2016) in a cross-sectional study of 913 
premenopausal women, found a significant association between self-reported smoking 
and serum AMH among women who smoked 20 or more cigarettes /day (−56.2%, 
95%CI: −80.3, −2.8%) [95]. Similar findings with number of pack-years smoked were 
reported by Dolleman et al. where significant association between smoking and age-
specific serum AMH was found for 10-15 pack-years (β= -7.0, p=0.003) and 15-20 pack-
years (β= -8.5, p=0.001) pack-years but not for 5-10 pack-years (β= -3.1, p=0.15) [59]. 
Other studies that reported significant inverse associations between smoking and 
ovarian reserve (as measured by AMH) reported moderate [16, 94, 95] to high [17, 20, 
21, 93] prevalence of smoking in the study population. Considering the established 
relationship between smoking and early age at menopause [142-146], it is plausible that
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smoking is associated with ovarian aging and reserve, but the association was not 
detected in this study due to low frequency of heavy smokers.  
Studies on the association of smoking with ovarian reserve varied in the 
covariates selected for adjustment. None of the studies controlled for PCOS, even though 
several of the studies [17, 20-22, 55, 93] were conducted among infertile or sub-fertile 
populations. Women with PCOS diagnosis have been shown to have significantly 
elevated AMH levels [63, 64]. In analyses that excluded women with PCOS diagnosis, 
effect sizes were generally stronger, suggesting PCOS is not only a confounder, but also 
an effect modifier of the association of smoking with ovarian reserve. Therefore, 
controlling for and stratifying on PCOS was a major improvement in the study design 
compared to prior studies. 
Timing of exposure may be a very important consideration for environmental 
predictors of AMH. For example, exposure to toxins during early development may be 
more influential on ovarian reserve than exposure as an adult. Experimental studies in 
animals shows that smoking inhibits follicular development; causes premature 
luteinization and atresia of the preovulatory follicle; reduces oocyte vascularization and 
maturation; impairs steroidogenesis; and increases chromosomal errors; and cytotoxicity; 
in a stage dependent manner [75-78]. Most studies on the association of smoking with 
ovarian reserve including this study, did not account for the timing of exposure. 
Effect Modification by Race 
Racial disparity in the association of smoking with ovarian reserve is largely 
unknown. The results of this study suggest that the risk of diminished ovarian reserve 
may be increased in African-American smokers.  Schuh-Huerta et al. (2011) in a 
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genome-wide association (GWA) analyses on hormonal markers of ovarian reserve 
(FSH and AMH) identified genome-wide significant SNPs associated with FSH 
(rs6543833, rs12465811, rs11255291) and AMH levels (rs9875589) in an African-
American population [16]. One SNP (rs12213875) identified in Caucasians was 
associated with a mean decrease of 1.3+1.4 pM in AMH among GG genotypes 
compared to an increase of 13.8+4.2 pM and 9.9+2.1 pM in the AA and AG 
genotypes, respectively [16]. While these results provide evidence for underlying 
genetic variations in ovarian reserve by race, disparities in environmental and 
behavioral factors such as smoking, also need to be explored. 
Effect Modification by NAT2 
This study is the first to explore population differences in NAT2 genotype 
frequencies as a possible reason for the inconsistency in the association of smoking 
with ovarian reserve. Results from this study, though not statistically significant, 
suggests that the risk of diminished ovarian reserve may be increased for current 
smokers who are slow NAT2 acetylators. Polymorphisms in the NAT2 gene modify 
susceptibility to harmful heterocyclic and aromatic amines constituents in tobacco 
smoke [25, 26, 100, 101]. High levels of DNA adduct of 4-aminobiphenyl, a 
carcinogenic aromatic amine in tobacco smoke, have been reported in tissues of 
smokers [103, 104, 106-112, 147]. Additionally, it has been shown that slow NAT2 
acetylators have variable reductions in catalytic activities that make them more 
susceptible to the effect of toxins [26, 100, 101, 114]. Given the significantly reduced 
fecundability reported among current smokers who are slow acetylators by Taylor et 
al. (2011), it is plausible that the effect is modulated through a reduction in ovarian 
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reserve. As reviewed earlier in this dissertation [29, 114, 117], slow acetylator NAT2 
phenotypes result from different mechanisms based on genotype, suggesting that the 
slow phenotype is not homogenous. Therefore, treating all slow acetylators as a single 
group may be diluting any effects present in a particular haplotype. Genetic 
heterogeneity of the slow NAT2 phenotype was investigated by assessing the 
interaction of smoking with individual NAT2 alleles and genotypes on ovarian reserve 
but analyses was limited by small sample size (data not shown). More studies, with a 
large sample size, are needed to clarify the role of NAT2 genotypes in the association 
of smoking with ovarian reserve. 
Strengths and Limitations 
Strengths of this study included the novel investigation of the impact of race 
and NAT2 acetylator status on the relationship of smoking with ovarian reserve in a 
diverse population of reproductive-age women. Comprehensive questionnaires 
permitted detailed characterization of exposure. Validation of exposure status with 
cotinine helped reduce misclassification error that may have occurred with use of 
self-report alone. Another strength of this study is with the use of an objective, a 
sensitive and reliable marker of ovarian reserve, AMH [58, 148, 149]. Studies show a 
high correlation between AFC and AMH [55, 56]. In addition, assessing information 
on outcome measures and covariates from medical records reduced the likelihood of 
differential information collection among smokers and nonsmokers. 
This study has several limitations which are peculiar to most cross-sectional 
study designs. Given the non-directionality and retrospective nature of the study 
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design, temporality cannot be established impacting the ability to infer a causal 
relationship between smoking and ovarian reserve.  
Recruiting participants from a single clinic may result in lack of 
generalizability. The study population may be significantly different from the general 
population of women in the U.S. limiting the generalizability of results of the study to 
populations not seeking fertility care. 
Another potential source of bias is missing information. Women excluded 
from the study for missing information on important variables may be different in 
significant ways from women who had complete data. For example, only 78% of all 
women who participated in the LOUSSI study had AMH levels measured. If some 
women declined a fertility workup, and those women were different from the women 
who agreed to do the work up with regard to their smoking status and AMH levels, 
selection bias could result. Based on the cost associated with pursuing fertility 
treatment [3, 4], it may be the case that women excluded are of low socioeconomic 
class, potentially compromising both internal and external validity. 
Recall bias is another potential limitation of this study. Although current 
smoking status was validated with cotinine, the dose and duration of exposure was 
largely based on self-report with the possibility of under-reporting (social desirability 
bias) or simply misremembering.  Smokers and former smokers under-reporting their 
exposure status may bias effect estimate towards the null. While access to medical 
records of participants provided access to important information relating to smoking 
and ovarian reserve, data on some important covariates were missing in some 
participants (alcohol use missing in 65%). For example, although the associations of 
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socioeconomic status and oral contraceptive use on ovarian reserve have not been 
established, it is uncertain how these unmeasured covariates may influence effect 
estimates obtained from this study. 
Finally, this study was limited by the small sample of smokers in the study 
population which reduced the power to detect the main effect of smoking or its’ 
potential interaction with race and NAT2 on ovarian reserve. Consequently, it cannot 
be certain whether the null associations are attributable to an actual lack of 
association or to inadequate statistical power. Future research should expand 
recruitment to other gynecological and fertility clinics and/or consider a meta-analysis 
to increase sample size. 
Conclusion 
Neither current cigarette smoking nor cumulative lifetime exposure to 
cigarette smoking was significantly associated with ovarian reserve in this study, 
although the directions of effect were consistent with the notion that smoking 
accelerates ovarian aging and follicle atresia. Larger and more representative studies 
are needed to better understand the relationship between smoking and ovarian 
reserve, especially for populations attempting pregnancy. As this study has set a 
precedent, future studies in this area should attempt to assess lifetime exposure to 
toxins from cigarette smoke with attention to dose and to particular developmental 
windows and should validate current smoking status with cotinine. 
Additional data is necessary to better define the role of race and NAT2 
polymorphisms with diminished ovarian reserve in women of reproductive-age 
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Supplemental Smoking and Hypertension Questionnaire 















LOUSSI SUPPLEMENTAL SMOKING QUESTIONNAIRE 
LIFETIME EXPOSURE TO TOBACCO SMOKE 
INSTRUCTIONS 
 
Dear Participant:   
Thank you for taking the time to answer this questionnaire. This form should take 5 to 10 
minutes to complete. Your answers will be used for research purposes only.  Your doctor 
will not know the answers you have marked.  Information gained from this study will help 
scientists and doctors understand the effect of smoking and secondhand smoke on 
fertility.   
 
This packet contains three questionnaires.   
Please choose ONE questionnaire to complete, depending on whether you are a 
current smoker, former smoker, or nonsmoker.  Leave the other two questionnaires 
blank. 
 
CURRENT SMOKERS:  Please answer Questionnaire 1.  You are considered a 
current smoker if you currently smoke at least 1 cigarette/week, or if you recently quit 
(less than 1 month ago) 
FORMER SMOKERS: Please answer Questionnaire 2.  You are considered a former 
smoker if you quit more than 1 month ago and used to smoke at least 1 cigarette/week. 
NONSMOKERS: Please answer Questionnaire 3. You are considered a nonsmoker if 
you have never smoked more than 1 cigarette/week. 
 
 
Please place questionnaire in the envelope provided and return it to the study 
personnel or place it inside the designated LOUSSI Study dropbox when you are 
finished.   
 
Thank you very much for your time! 
 
QUESTIONNAIRE 1 (FOR CURRENT SMOKERS) 
Answer this questionnaire if you currently smoke at least 1 cigarette/week,  
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or if you quit smoking less than 1 month ago. 
Smoking History 
1.  How many years have you been smoking (at least 1 cigarette/week)? _____ 
years 
 
(If you have smoked on and off, please add up the total number of years 
you smoked.)  
 
 
2. On the average, how many cigarettes (or packs) do you now smoke per day?  
 
___ cigarettes/day or ____ packs/day  
 
(If you quit less than 1 month ago, please indicate how much you used to 
smoke before you quit.) 
 
 
Secondhand Smoke  
 
 
3.   Think about your home when you were growing up (less than 18 years 
old). On average, how often were you exposed to secondhand smoke inside 
your home? (For example, how often did your parents, guardians, or siblings 
smoke inside the home?) 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
 
4.  Think about your home in the past year.  How often have you been exposed 
to secondhand smoke inside your home? 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
 
5.   Think about other places you go on a regular basis. (For example, a friend or 
relative’s house, your workplace, bars or restaurants, in your car or someone 
else’s car, etc.)  In the past year, how often have you been exposed to 
secondhand smoke inside other places besides your home? 
Never  Rarely    Often   Every day 




                                                                                                                   Please see 
back →  
 
6.    Does anyone else living in your home smoke cigarettes, cigars or a pipe? 
☐ Yes 
☐ No 
If you answered “Yes”, how many other people living in your home smoke these 
tobacco products? 
____Enter number 
     What is your relationship with the smoker(s)? (Check all that apply) 




Other sources of nicotine 
 
 
7.   Please check whether you have used any of the following in the past week: 
 
_____ Nicotine patches 
_____ Nicorette gum or similar 
_____ E-cigarettes 
_____ Smokeless tobacco or chewing tobacco 





QUESTIONNAIRE 2 (FOR FORMER SMOKERS)  
Answer this questionnaire if you used to smoke at least 1 cigarette/week and quit 




1.   When is the last time you smoked a cigarette?  (Month, Year) ____, ______ 
 
2.  How many years did you smoke at least 1 cigarette/week?    ____years 
(If you smoked on and off, please add up the total number of years you smoked.)  
 
 
3.  On the average, how many cigarettes (or packs) did you used to smoke per 
day?  
 
___ cigarettes/day or ____ packs/day  
 
Secondhand Smoke  
 
 
4.   Think about your home when you were growing up (less than 18 years 
old). On average, how often were you exposed to secondhand smoke inside 
your home? (For example, how often did your parents, guardians, or siblings 
smoke inside the home?) 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
 
5.  Think about your home in the past year.  How often have you been exposed 
to secondhand smoke inside your home? 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
 
6.   Think about other places you go on a regular basis. (For example, a friend or 
relative’s house, your workplace, bars or restaurants, in your car or someone 
else’s car, etc.)  In the past year, how often have you been exposed to 
secondhand smoke inside other places besides your home? 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
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                                                                                                                       Please see 
back →  
 
7.    Does anyone living in your home smoke cigarettes, cigars or a pipe? 
☐ Yes 
☐ No 
If you answered “Yes”, how many people living in your home smoke these tobacco 
products? 
____Enter number 
     What is your relationship with the smoker(s)? (check all that apply) 




Other sources of nicotine 
 
 
8.   Please check whether you have used any of the following in the past week: 
 
_____ Nicotine patches 
_____ Nicorette gum or similar 
_____ E-cigarettes 
_____ Smokeless tobacco or chewing tobacco 





QUESTIONNAIRE 3 (FOR NONSMOKERS) 
 
Answer this if you have never smoked more than 1 cigarette/week 
The goal of this questionnaire is to determine how much exposure to secondhand smoke 
you have had in your lifetime. 
Secondhand Smoke  
 
 
1. Think about your home when you were growing up (less than 18 years 
old). On average, how often were you exposed to secondhand smoke inside 
your home? (For example, how often did your parents, guardians, or siblings 
smoke inside your home?) 
 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
 
 
2. Think about your home in the past year.  How often have you been exposed 
to secondhand smoke inside your home? 
 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
 
3. Think about other places you go on a regular basis. (For example, a friend or 
relative’s house, your workplace, bars or restaurants, in your car or someone 
else’s car, etc.)  In the past year, how often have you been exposed to 
secondhand smoke inside other places besides your home? 
 
Never  Rarely    Often   Every day 
  (less than once/week) (1-6 days/week)  
4.  Does anyone living in your home smoke cigarettes, cigars or a pipe? 
☐ Yes   ☐ No 
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If you answered “Yes”, how many people living in your home smoke these 
tobacco products? 
____Enter number 
What is your relationship with the smoker(s)? (check all that apply) 
____Spouse or partner 




Other sources of nicotine 
 
 
5.   Please check whether you have used any of the following in the past week: 
 
_____ Nicotine patches 
_____ Nicorette gum or similar 
_____ E-cigarettes 
_____ Smokeless tobacco or chewing tobacco 






Data Collection Forms 
Sample of data entry form for past medical and social history; anthropometric measures; 
















DATA COLLECTION FORM   Subject Identification Number: __________________ 
1. Self-reported data From most recent Patient History Form  (New patient info)
 
Date of first visit (MM/YY):________________ 
 
Date of study enrollment (MM/YY):________ 
 
Age (years) at enrollment: ________________ 
 
Height: (feet, inches): ______feet_____inches 
 
Weight: _________pounds or __________ kg 
 
Body mass index: _________________kg/m2 
 
Total number of previous pregnancies: _____ 
 
Regular periods (yes/no): ________________ 
 
Average menstrual cycle length: _______days 
 
Age at first period: _________________years 
 
Sexually transmitted infections: _____(yes/no) 
 
   If yes, list:___________________________ 
 






Partner/no partner? ____________________ 
 
Length of time with current partner: _______ 
 
Routine exercise (yes/no): ____________ 
  
Routine exposure to chemicals(Yes/no):______ 
 
If yes, list here: ________________________ 
 








     for how many years? ___________ 
 
Ever smoked 100 cigarettes? ________ 
 








Drugs (e.g. marijuana) (yes/no) _______ 
 
Ancestry or Race _________________ 
 




Patient History Forms 
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